Drugs /

obinutuzumab

Back to Drugs List
Associated Genetic Biomarkers

Overview

Generic Name(s):
obinutuzumab
Trade Name(s):
Gazyva and Gazyvaro
NCI Definition [1]:
A glycoengineered, humanized IgG1 monoclonal antibody with potential antineoplastic activity. Obinutuzumab, a third generation type II anti-CD20 antibody, selectivity binds to the extracellular domain of the human CD20 antigen on malignant human B cells. The Fc region carbohydrates of the antibody, enriched in bisected non-fucosylated glycosylation variants, contribute to its higher binding affinity for human FcgammaRIII receptors compared to non-glycoengineered antibodies, resulting in enhanced antibody-dependent cellular cytotoxicity (ADCC) and caspase-independent apoptosis. In addition, modification of elbow hinge sequences within the antibody variable framework regions may account for the strong apoptosis-inducing activity of R7159 upon binding to CD20 on target cells.

Clinical Trials

View Clinical Trials for obinutuzumab

Obinutuzumab has been investigated in 74 clinical trials, of which 69 are open and 5 are closed. Of the trials investigating obinutuzumab, 21 are phase 1 (20 open), 10 are phase 1/phase 2 (8 open), 33 are phase 2 (31 open), 9 are phase 3 (9 open), and 1 is phase 4 (1 open).

MS4A1 Expression, BCL2 Fusion, and BCL6 Fusion are the most frequent biomarker inclusion criteria for obinutuzumab clinical trials.

Follicular lymphoma, chronic lymphocytic leukemia, and diffuse large B-cell lymphoma are the most common diseases being investigated in obinutuzumab clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Obinutuzumab
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Obinutuzumab
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating obinutuzumab and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
humab(cd20), ro5072759, immunoglobulin g1, anti-(human cd20 (antigen)) (human-mouse monoclonal ga101 heavy chain), disulfide with human-mouse monoclonal ga101 kappa-chain, dimer, ro-5072759, ga 101, obinutuzumab (substance), afutuzumab, ga-101, ga101 antibody, ro 5072759, anti-cd20 monoclonal antibody r7159, Gazyvaro, ga101, afutuzumab, r7159, anti-cd20 monoclonal antibody r7159, obinutuzumab, obinutuzumab (product), obinutuzumab, Gazyva
Drug Categories [2]:
Immunotherapies, Therapeutic antibodies
Drug Target(s) [2]:
MS4A1
NCIT ID [1]:
C70741
SNOMED ID [1]:
R-FF6F7

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.